- Home
- GNLX vs ARMP Comparison
GNLX vs ARMP Comparison
Compare GNLX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ARMP
- Stock Information
- Founded
- GNLX 2001
- ARMP N/A
- Country
- GNLX United States
- ARMP United States
- Employees
- GNLX N/A
- ARMP N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- ARMP Health Care
- Exchange
- GNLX Nasdaq
- ARMP Nasdaq
- Market Cap
- GNLX 128.0M
- ARMP 92.4M
- IPO Year
- GNLX 2023
- ARMP N/A
- Fundamental
- Price
- GNLX $4.09
- ARMP $2.88
- Analyst Decision
- GNLX Strong Buy
- ARMP Strong Buy
- Analyst Count
- GNLX 4
- ARMP 1
- Target Price
- GNLX $17.75
- ARMP $9.00
- AVG Volume (30 Days)
- GNLX 147.7K
- ARMP 11.8K
- Earning Date
- GNLX 11-13-2025
- ARMP 11-12-2025
- Dividend Yield
- GNLX N/A
- ARMP N/A
- EPS Growth
- GNLX N/A
- ARMP N/A
- EPS
- GNLX N/A
- ARMP N/A
- Revenue
- GNLX N/A
- ARMP $6,868,000.00
- Revenue This Year
- GNLX N/A
- ARMP $8.43
- Revenue Next Year
- GNLX N/A
- ARMP N/A
- P/E Ratio
- GNLX N/A
- ARMP N/A
- Revenue Growth
- GNLX N/A
- ARMP 84.67
- 52 Week Low
- GNLX $1.95
- ARMP $0.90
- 52 Week High
- GNLX $5.89
- ARMP $3.14
- Technical
- Relative Strength Index (RSI)
- GNLX 66.57
- ARMP 52.94
- Support Level
- GNLX $3.56
- ARMP N/A
- Resistance Level
- GNLX $3.61
- ARMP $3.03
- Average True Range (ATR)
- GNLX 0.24
- ARMP 0.15
- MACD
- GNLX 0.05
- ARMP -0.10
- Stochastic Oscillator
- GNLX 94.05
- ARMP 91.72
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.